Breaking News

Wheeler Bio Closes $35M Series A-1 Financing Round

Paves the way for future growth, including building a 52,000-square-foot large-scale biologics manufacturing facility in Oklahoma City.

Author Image

By: Charlie Sternberg

Associate Editor

Wheeler Bio, a contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of antibody-based therapies, has closed an oversubscribed Series A-1 financing round. The $35 million round was led by Alloy Therapeutics and Echo Investment Capital (Echo), with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises. Wheeler Bio is built upon its foundational scientific platform, Modular CMC. A...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters